

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Jones Jeanne M</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>10/17/2022</u>		3. Issuer Name and Ticker or Trading Symbol <u>EXELON CORP [ EXC ]</u>	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>EVP &amp; CFO</u>		5. If Amendment, Date of Original Filed (Month/Day/Year)	
<u>10 S DEARBORN STREET</u> <u>54TH FLOOR</u>					6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(Street)						
<u>CHICAGO</u>	<u>IL</u>	<u>60603</u>				
(City)	(State)	(Zip)				

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>3,485</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Restricted Stock Unit Award (01/27/2020)</u>	<u>(1)</u>	<u>(1)</u>	<u>Common stock</u>	<u>1,147<sup>(1)</sup></u>	<u>(1)</u>	<u>D</u>
<u>Restricted Stock Unit Award (01/25/2021)</u>	<u>(2)</u>	<u>(2)</u>	<u>Common stock</u>	<u>2,407<sup>(2)</sup></u>	<u>(2)</u>	<u>D</u>
<u>Restricted Stock Unit Award (01/28/2022)</u>	<u>(3)</u>	<u>(3)</u>	<u>Common stock</u>	<u>3,917<sup>(3)</sup></u>	<u>(3)</u>	<u>D</u>
<u>Earned Performance RSU</u>	<u>(4)</u>	<u>(4)</u>	<u>Common stock</u>	<u>6,691<sup>(4)</sup></u>	<u>(4)</u>	<u>D</u>
<u>Restricted Stock Unit Award (01/29/2018)</u>	<u>(5)</u>	<u>(5)</u>	<u>Common stock</u>	<u>19,776<sup>(5)</sup></u>	<u>(5)</u>	<u>D</u>

**Explanation of Responses:**

1. Remaining 1/3 increment of annual restricted stock unit (RSU) award granted in January 2020 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
2. Remaining 2/3 increment of annual RSU award granted in January 2021 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
3. Annual RSU award granted in January 2022 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation Committee's January or February meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
4. RSU award granted pursuant to the Exelon Long Term Incentive Plan; Award cliff vests at the January 2023 meeting of the Compensation Committee with each RSU representing the right to receive one share of Exelon common stock upon vesting.
5. Restricted stock unit award granted pursuant to the Exelon Long Term Incentive Plan. All shares will cliff vest at the January 2023 meeting of the Compensation Committee with each RSU representing the right to receive one share of Exelon common stock upon vesting.

Elizabeth M. Hensen, Attorney-in-Fact 10/24/2022  
for Jeanne M Jones

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**EXELON**  
**Section 16 Report**

The undersigned hereby constitutes and appoints M. Hensen, Melissa E. Ramirez or Tom Boine as attorney-in-fact to:

- (1) execute for and on behalf of the undersigned as a director of Exelon Corporation (“*Exelon*”) a Section 16(a) of the Securities Exchange Act of 1934 (including EDGAR Form ID, Forms and *Reports*”);
- (2) do and perform any and all acts for and on behalf of the undersigned as desirable to complete and execute the undersigned’s amendment or amendments thereto under the Securities and Exchange Commission’s rules and regulations;
- (3) take any other action of any type and in any capacity in the opinion of such attorney-in-fact, made by, the undersigned, it being understood that the undersigned on behalf of the undersigned pursuant to this power of attorney contain such terms and conditions as may be determined in the attorney-in-fact’s discretion.

The undersigned hereby grants to each such any and every act and thing whatsoever req of the rights and powers herein granted, as could do if personally present, with full confirming all that such attorney-in-fact, lawfully do or cause to be done by virtue granted. The undersigned acknowledges th at the request of the undersigned, are not responsibilities to comply with Section 16 o

This Power of Attorney shall remain in full f file Section 16 Reports with respect to the u by Exelon, unless earlier revoked by the attorneys-in-fact.

**IN WITNESS WHEREOF**, the undersigne as of this 11th day of October 2022.

By:

Name: Jeanne M Jones

A handwritten signature in black ink, appearing to read "Jeanne M Jones", is written over a solid horizontal line. The signature is cursive and includes a large loop at the beginning and a long, sweeping tail.

